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Introduction {#sec1}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causative agent of the ongoing pandemic coronavirus disease 2019 (COVID-19) ([@bib35]). SARS-CoV-2 emerged in Wuhan, China in December 2019 and rapidly spread to more than 175 countries within three months ([@bib38], [@bib103]). As of May 18, 2020, about 4.7 million confirmed cases and \> 316,000 deaths have been reported worldwide. The absence of approved vaccines and only a single emergency-use FDA-approved therapeutic against SARS-CoV-2 hinders pandemic control.

The genome of SARS-CoV-2 is an ∼30 kb RNA predicted to encode 16 non-structural proteins (nsp1--nsp16), four structural proteins (spike, membrane, envelope, and nucleocapsid), and eight accessory proteins (3a, 3b, 6, 7a, 7b, 8b, 9b, and 14) ([@bib93]), expressed from genome-length or sub-genomic mRNAs. The spike (S) glycoprotein mediates viral entry via binding to the human angiotensin-converting enzyme (ACE2) ([@bib37], [@bib86], [@bib97]), followed by proteolytic processing by transmembrane protease, serine 2 (TMPRSS2), furin, and perhaps other lung proteases, which trigger fusion of viral and cellular membranes. Spike glycoprotein is also the main target of host neutralizing antibodies (nAbs) ([@bib37]).

SARS-CoV-2 infection primarily targets the respiratory tract. A fraction of SARS-CoV-2 infections manifest as bilateral lower-zone pneumonias and diffuse alveolar damage (DAD) that might progress to acute respiratory distress syndrome (ARDS), especially in the aged and individuals with co-morbidities ([@bib13], [@bib36]). In comparison to symptoms of MERS-CoV and SARS-CoV 2003 infections, clinical symptoms of COVID-19 are broader and more variable ([@bib38], [@bib64], [@bib92], [@bib103]). Differences in transmissibility and viral shedding suggest the *in vivo* replication sites and/or replication efficiency of SARS-CoV-2 differ significantly from SARS-CoV ([@bib65], [@bib90], [@bib104]).

A wealth of single-cell RNA sequencing (scRNA-seq) data have been mobilized to describe the expression of ACE2 and TMPRSS2 with emphasis on the human respiratory tract ([@bib2], [@bib73], [@bib81]). However, complementary techniques are needed to describe the organ-level architecture of receptor expression, improve on the sensitivity of scRNA for low-expression genes, e.g., ACE2, and to describe the function of ACE2, i.e., mediate infectivity. Accordingly, a combination of RNA *in situ* hybridization (RNA-ISH) techniques, a novel set of SARS-CoV-2 reporter viruses produced by reverse genetics, and primary cultures from all affected regions of the respiratory tract was assembled for our investigations.

We utilized the reverse genetics systems to test for protection and/or durability of protection afforded by convalescent serum and/or SARS-CoV-2-specific monoclonal antibodies (mAbs) and antigenicity relationships between SARS-CoV and SARS-CoV-2 after natural human infections. These tools were also utilized to contrast two non-exclusive hypotheses that might account for key aspects of SARs-CoV-2 transmission and pathogenesis: (1) transmission is mediated by airborne microparticles directly infecting the lung ([@bib59], [@bib89]); or (2) the nose is the initial site of infection, followed by aspiration of the viral inoculum from the oropharynx into the lung ([@bib22], [@bib90]). Accordingly, we characterized the ACE2 and TMPRSS2 expression amounts in the nose and lung and in parallel the SARS-CoV-2 infection of human nasal, bronchial, bronchiolar, and alveolar epithelial cultures. These findings were compared with virus distributions and tropisms in lungs from lethal COVID-19 cases.

Results {#sec2}
=======

Recombinant viruses replicate similarly to the SARS-CoV-2 clinical isolate *in vitro* {#sec2.1}
-------------------------------------------------------------------------------------

A full-length infectious complementary DNA (cDNA) clone of a US SARS-CoV-2 clinical isolate WA1 was generated by cloning seven genomic fragments separately into vector plasmids ([Figure 1](#fig1){ref-type="fig"} A). Additionally, two reporter viruses were constructed by replacing a 276-bp region in ORF7 with a green fluorescent protein (GFP) or a GFP-fused nanoluciferase (nLuc) gene ([Figure 1](#fig1){ref-type="fig"}A). After assembly into full-length cDNA, full-length RNA was electroporated into Vero-E6 cells ([@bib76], [@bib100]). After recovering the wild-type (WT), icSARS-CoV-2-GFP, and icSARS-CoV-2-nLuc-GFP recombinant viruses, viral replication was confirmed by the presence of sub-genomic-length leader-containing RNA transcripts 20 h after electroporation ([Figure S1](#figs1){ref-type="fig"} ). All three recombinant viruses replicated ([Figure S1](#figs1){ref-type="fig"}), generated similar plaques in Vero E6 cells, and could be passaged serially in the cell culture without exogenous trypsin ([Figure 1](#fig1){ref-type="fig"}B). We defined cytopathic effect (CPE) by cell rounding and detachment from monolayers. GFP signals were evident in cells two days after transfection with RNA transcripts from both indicator viruses ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Design and recovery of SARS-CoV-2 recombinant viruses(A) Full-length cDNA clone constructs and genomes of recombinant viruses. Restriction sites, cohesive ends, and the genetic marker T15102A (^∗^) are indicated in the schematic diagram. GFP or GFP-fused nLuc genes were introduced into the ORF7 (replacing aas 14--104) of SARS-CoV-2 genome.(B) Plaques of recombinant viruses.(C) CPE and GFP signals were observed in Vero-E6 cells electroporated with sub-genomic RNA (sgRNA)-N alone (mock) or sgRNA-N mixed with full-length RNA transcripts (recombinant viruses) at two days after transfection. Scale bar, 100 μm.(D and E) SacI digestion (D) and Sanger sequencing (E) of a 1.5-kb region covering the genetic marker in vial genomes.(F) Northern blot analysis of genomic and sgRNAs isolated from the virus-infected cells. Abbreviations are as follows: Isolate, clinical isolate strain WA1; WT, icSARS-CoV-2-WT; GFP, icSARS-CoV-2-GFP, nLuc-GFP: icSARS-CoV-2-nLuc-GFP.See also [Figure S1](#figs1){ref-type="fig"}.Figure S1Additional information for the SARS-CoV-2 infectious cDNA clone, related to [Figure 1](#fig1){ref-type="fig"}(A) Electrophoresis of seven restriction enzyme-digested infectious cDNA clone plasmids. Plasmid A was digested with NotI and BsaI; plasmids B, C, and D were digested with BsaI; plasmids E and F were digested with BsmBI; plasmid G was digested with SalI and BsaI.(B) Amplification SARS-CoV-2 sgRNAs using primers targeting sgRNA-5 (M) and −9 (N). Cellular RNA samples were collected from Vero-E6 cells electroporated with viral RNA transcripts at 20 h. Mock cells were electroporated with SARS-CoV-2 sgRNA-9 alone.(C) Alignment of sequences containing the T \#15102 in nsp12 gene among 9 different group 2b CoVs.

To distinguish our recombinant viruses from the circulating SARS-CoV-2 strains, we introduced a silent mutation (T15102A) into a conserved region in nsp12 to ablate an endogenous SacI site in the molecular clone ([Figure S1](#figs1){ref-type="fig"}). We confirmed the presence of this mutation in all three recombinant viruses but not in the clinical SARS-CoV-2 isolate via Sanger sequencing and PCR amplification followed by SacI digestion ([Figures 1](#fig1){ref-type="fig"}D and 1E). To evaluate viral RNA synthesis, we performed Northern blot analyses that showed that the number of sub-genomic RNA (sgRNA) bands was equivalent in the recombinant and clinical isolates, confirming the presence of eight principle sub-genomic mRNAs during infection ([Figure 1](#fig1){ref-type="fig"}F). As expected, the molecular weights of sgRNA 2 to sgRNA 7 in the two reporter viral samples were higher than those in the clinical isolate and WT samples, reflecting the insertion of the 720-bp GFP gene or the 1,233-bp nLuc-GFP gene into the 366-bp ORF7 genetic location. These data also demonstrated that ORF7 was not essential for *in vitro* replication of SARS-CoV-2.

Next, we evaluated one-step (multiplicity of infection \[MOI\] = 5) and multi-step (MOI = 0.05) growth curves of the three recombinant viruses in Vero E6 cells in comparison to the clinical isolate WA1 strain. The titer of all SARS-CoV-2 increased and plateaued to mid-10^6^ plaque-forming units (PFU)/mL within 12--18 h in the one-step curve and within 36--48 h in the multi-step curve ([Figures 2](#fig2){ref-type="fig"}A and 2B). In contrast to other reported indicator viruses ([@bib83]), the three recombinant viruses replicated to titers equivalent to the clinical isolate.Figure 2Growth curves and the role of proteases in SARS-CoV-2 replication(A and B) One-step (A) and multi-step (B) growth curves of clinical isolate and recombinant viruses in Vero E6 cells, with MOI of 5 and 0.05, respectively.(C and D) Fluorescent images (C) and viral titers (D) of the SARS-CoV-2-GFP replicates in Vero cells supplemented with different concentrations of trypsin.(E and F) Fluorescent images (E) and viral titers (F) of the SARS-CoV-2-GFP replicates in normal Vero or Vero-furin cells.(G and H) Fluorescent images (G) and viral titers (H) of the SARS-CoV-2-GFP replicates in normal LLC-MK or LLC-MK-TMPRSS2 cells.All scale bars, 200 μm. Data are presented in mean ± SD.See also [Figure S2](#figs2){ref-type="fig"}.

Serine proteases TMPRSS2 and Furin, but not exogenous Trypsin, enhance the replication of SARS-CoV-2 {#sec2.2}
----------------------------------------------------------------------------------------------------

Host proteases, including cell surface and intracellular proteases, play an essential role in CoV infection by processing the S protein to trigger membrane fusion ([@bib41], [@bib54], [@bib53], [@bib57], [@bib58], [@bib88]). Therefore, we evaluated the multi-step replication (MOI = 0.03) of the icSARS-CoV-2-GFP in the presence of selected proteases via fluorescent microscopy and measurements of viral titer.

Vero cells were infected with the icSARS-CoV-2-GFP reporter virus in the presence of 0, 1, or 5 μg/mL of trypsin. Unlike some coronaviruses (CoVs) ([@bib57], [@bib88]), trypsin did not trigger syncytium formation, and at 24 and 48 h, a slightly higher percentage of trypsin-exposed cells expressed GFP signals and CPE than did controls ([Figures 2](#fig2){ref-type="fig"}C and [S2](#figs2){ref-type="fig"} ). Trypsin also resulted in slightly lower virus titers than controls ([Figure 2](#fig2){ref-type="fig"}D), suggesting that trypsin impairs the stability of viral particles in supernatants.Figure S2Cytopathic Effect of Cells Infected with icSARS-CoV-GFP Virus, related to [Figure 2](#fig2){ref-type="fig"}(A) Infected Vero cells supplemented with different concentrations of trypsin.(B) Infected Vero or Vero-furin cells.(C) Infected LLC-MK or LLC-MK-TMPRSS2 cells.All scale bars, 200 μm.

SARS-CoV-2 S protein exhibits a novel 4 amino acid (aa) furin-cleavage site "RRAR" at the junction between S1 and S2 subunits ([@bib5], [@bib20]). We observed increased icSARS-CoV-2-GFP expression in the furin-overexpressing versus WT cells at 24 h ([Figure 2](#fig2){ref-type="fig"}E), correlating with 1 log~10~ higher infectious titers than WT Vero cells at early times after infection ([Figure 2](#fig2){ref-type="fig"}F). Moreover, extensive CPE was noted in furin cells versus parental Vero cell cultures ([Figure S2](#figs2){ref-type="fig"}). In contrast, enhanced expression of TMPRSS2 in a rhesus monkey kidney epithelial cell line, LLC-MK cells, resulted in higher amounts of GFP expression and higher icSARS-CoV-2-GFP titers ([Figures 2](#fig2){ref-type="fig"}G and 2H). These data suggest that serine proteases like furin and TMPRSS2 enhance the replication efficiency and cytopathology of SARS-CoV-2 *in vitro*.

The neutralization sensitivity of SARS-CoV-2 nLuc virus to potent SARS and MERS monoclonal antibodies and polyclonal sera {#sec2.3}
-------------------------------------------------------------------------------------------------------------------------

Three neutralization assays were developed utilizing luciferase reporter CoVs, including SARS-CoV, MERS-CoV, and SARS-CoV-2 ([Figures 3](#fig3){ref-type="fig"} A--3H). Previous studies have identified remarkably potent SARS and MERS nAbs that target receptor binding domains and exhibit strong neutralizing activities *in vitro* and *in vivo* ([@bib98], [@bib101], [@bib102]). We utilized three highly cross-reactive nAb against SARS-CoV (S230, S230.15, and S227.9), two nAbs against MERS-CoV (MERS-27 and m336), and one broadly cross-reactive nAb against Dengue virus (EDE1-C10). We also tested a pooled mouse serum sample collected from BALB/c mice vaccinated and boosted with a Venezuelan equine encephalitis virus viral replicon particle (VRP-SARS-COV-2-S) encoding the SARS-CoV-2 S gene. The boost was performed three weeks after vaccination, and sera were collected one week before and one week after boost.Figure 3Neutralization assays using luciferase reporter coronaviruses(A and B) mAbs (A) and COVID-19 sera (B) against icMERS-CoV-nLuc.(C and D) mAbs (C) and SARS and COVID-19 sera (D) against icSARS-CoV-nLuc.(E--G) mAbs (E), SARS and COVID-19 sera (F), and vaccinated mouse serum (G) against icSARS-CoV-2-nLuc-GFP.(H) ID~50~ values of SARS and COVID-19 sera cross-neutralizing SARS-CoV and SARS-CoV-2. The same sera samples are indicated with arrows.The MERS-CoV neutralizing mAbs were the following: MERS-27 and m336; the SARS-CoV neutralizing mAbs were the following: S230, S230.15, and S227.9; the Dengue virus mAb was the following: EDE1-C10. SARS patient serum samples are labeled as "A" to "E"; COVID-19 patient serum samples are labeled as "1" to "10". Mouse serum was produced by immunized BALB/c mice with SARS-CoV-2 spike.

Both the MERS nAbs, MERS-27 and m336, neutralized the icMERS-CoV-nLuc virus but not the 2003 SARS-CoV-nLuc or 2019 SARS-CoV-2-nLuc-GFP recombinant viruses. Similarly, the three SARS nAbs, S230, S230.15, and S227.9 exhibited potent neutralization activities against icSARS-CoV-nLuc, but not icSARS-CoV-2-nLuc-GFP ([Figures 3](#fig3){ref-type="fig"}A, 3C, and 3E). As a negative control, a Dengue virus nAb EDE1-C10 did not neutralize any of the three tested CoVs. Importantly, the mouse serum sample neutralized 99.4% of the icSARS-CoV-2-nLuc-GFP virus at a 1:2 dilution after prime, and much more potent neutralization was noted after VRP-SARS-CoV-2-S boost ([Figure 3](#fig3){ref-type="fig"}G).

The S proteins of SARS-CoV and SARS-CoV-2 share 75% identity in amino acid sequences. To investigate whether SARS-CoV and SARS-CoV-2 infections elicit cross-neutralizing antibodies, we evaluated five serum samples from patients who survived the 2003 SARS-CoV Toronto outbreak and 10 serum samples from COVID-19 survivors by using nLuc neutralization assays with the two reporter CoVs. All five 2003 SARS serum samples demonstrated high neutralization titers against SARS-CoV-nLuc virus, and half-maximal inhibitory dilution (ID~50~) activities in the range were from 1:30.6 to 1:376.5 ([Figure 3](#fig3){ref-type="fig"}F). Surprisingly, two of these serum samples, A and E, neutralized icSARS-CoV-2-nLuc-GFP with 11.9- and 8.1-fold of decreases in ID~50~, respectively. In contrast, 10 COVID-19 convalescent serum samples displayed variable neutralization ID~50~ titers that ranged from 61.67 to 782.70 against icSARS-CoV-2-nLuc-GFP but little, if any, neutralization of 2003 icSARS-CoV-nLuc or icMERS-CoV-nLuc viruses at the lowest dilutions tested ([Figures 3](#fig3){ref-type="fig"}B, 3D, and 3H).

RNA *in situ* hybridization localization of the SARS-CoV-2 receptor complex in the normal human upper and lower respiratory tract {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------------

The sites of SARS-CoV-2 infection in the upper airways (nose and oropharynx) and lung (lower airways and alveoli) are under active investigation ([@bib71]). Accordingly, we characterized ACE2 and TMPRSS2 expression in these regions by using RNA-ISH ([Figures 4](#fig4){ref-type="fig"} and [S3](#figs3){ref-type="fig"} ). Consistent with the low amount of ACE2 expression reported from scRNA-seq data ([@bib12], [@bib23], [@bib73]), low amounts of ACE2 were detected in the respiratory epithelium lining the nasal cavity ([Figure 4](#fig4){ref-type="fig"}A). Scattered, low amounts of ACE2 and TMPRSS2 expression were also observed in the squamous epithelium lining oropharyngeal tonsillar tissue ([Figure S3](#figs3){ref-type="fig"}A). Notably, progressively reduced amounts of ACE2 expression were observed in the lower airway regions, culminating in minimal amounts in the alveolar region. Quantitative comparisons of nasal and bronchial airway epithelia obtained as brush samples simultaneously from the same subjects by qPCR revealed significantly higher expression of ACE2 but not TMPRSS2 in the nasal than the bronchial tissues ([Figure 4](#fig4){ref-type="fig"}B). In a separate qPCR study, there was a gradient of reduced ACE2 expression from proximal to distal intrapulmonary regions ([Figure 4](#fig4){ref-type="fig"}C). In contrast, TMPRSS2 mRNA exhibited an overall higher expression amount in all respiratory tract regions than ACE2.Figure 4Intraregional *ACE2* and *TMPRSS2* mRNA expression in normal human airways(A) Representative RNA*-*ISH images demonstrating regional distribution of *ACE2* and *TMPRSS2* mRNA localization (red signal) in normal human airway surface epithelium. Scale bars, 20 μm.(B) Comparison of *ACE2* and *TMPRSS2* mRNA expression between matched nasal and bronchial brushed tissues obtained from seven healthy subjects.(C) Relative expression of *ACE2* and *TMPRSS2* mRNA in different airway regions enriched for epithelial cells, including tracheas, bronchi, bronchiole, and alveoli, obtained from matched seven normal lungs.(D) Frequency of *ACE2*^+^ and *TMPRSS2*^+^ cells among total cells identified in distinct anatomical airway regions in a re-analysis of scRNA-seq data ([@bib21]).(E) RNA-ISH images depicting mRNA expression of *ACE2* and cell type markers, including *FOXJ1* (ciliated) (i, ii, and iv), *MUC5B* (secretory) (iii and v), *SFTPC* (alveolar type 2) (vi), and *HOPX* (alveolar type 1 or 2) (vii) on cytospins of nasal versus bronchial superficial epithelial and purified alveolar cells. Scale bars, 10 μm.(F) Frequency of *ACE2*^+^ cells among nasal and bronchial preparations. A total of 1,000 cells were analyzed for *ACE2* expression per donor (N = 3).G. Frequency of *ACE2*^+^ cells among *FOXJ1*^*+*^ or *MUC5B*^+^ cells in nasal or bronchial preparations. A total of 200 *FOXJ1*^+^ or *MUC5B*^+^ cells were analyzed for *ACE2* expression per donor (N = 3).(H and I) Histograms depicting number of dot signals of *ACE2* expression in *FOXJ1* or *MUC5B*^+^ cells in nasal (H) or bronchial (I) preparations identified by scRNA-ISH. *ACE2*^+^ dot signals were counted in 200 *FOXJ1* or *MUC5B*^+^ cells per donor (N = 3). Statistics for (B), (C), (F), and (G) used linear mixed-effect model with the donor as random-effect factor for comparison between groups, and pairwise comparisons of groups with more than two levels were performed using Tukey post hoc tests. (H) and (I) used generalized linear mixed-effect models with Poisson distribution to compare the difference in cell counts at varying *ACE2* expression amounts between *FOXJ1*^+^ and *MUC5B*^+^ cells. Histobars and error bars represent mean ± SD. Different symbol colors indicate results from different individual donors.See also [Figure S3](#figs3){ref-type="fig"}.Figure S3*ACE2* and *TMPRSS2* expression in human tonsillar epithelium and nasal surface epithelium and submucosal glands, related to [Figure 4](#fig4){ref-type="fig"}(A) Tonsillar surface squamous epithelium stained with (i) H&E staining and (ii) dual-color-fluorescence RNA-ISH showing *TMPRSS2* (green) and *ACE2* (red) along with nuclear staining (blue). Scale bars, 50 um. (iii) Enlarged images of (ii) showing surface (iii) and basal (iv) expression; scale bars, 20um. Images are representative from N = 3 tonsils, N = 4-8 regions per tonsil. (v) Signal dots for *ACE2* and *TMPRSS2* mRNAs were counted and normalized to the number of cells in surface and basal layer of tonsillar surface epithelium as described in the [STAR Methods](#sec4){ref-type="sec"}. Each bar represents the average of N = 4-8 regions for each tonsil studied. Data are presented in mean ± SD.(B) Frequency of *FOXJ1*- or *MUC5B*-positive cells identified by RNA-ISH among total nasal surface epithelial cells isolated. A total of 1,000 cells were analyzed for *FOXJ1* or *MUC5B* expression per donor. N = 3.(C) Cytospins of nasal submucosal glands cells probed by dual-color-immunofluorescent RNA-ISH. (i) shows lack of *ACE2* in *MUC5B*-positve nasal gland cells, while (ii) depicts occasional co-expression of *TMPRSS2* in a subset of *MUC5B*-positive cells. Scale bars, 20 μm. (iii) Frequency of detection of *ACE2* or *TMPRSS2* positive cells in *MUC5B* positive cells from nasal glands. N = 1 gland preparation, a total of 200 *MUC5B* positive cells were counted.

Previously reported scRNA-seq data describing ACE2 and TMPRSS2 expression in the upper and lower respiratory system have detected ACE2 in ∼5% of total cells interrogated ([@bib21], [@bib73]) ([Figure 4](#fig4){ref-type="fig"}D). We recently developed a single-cell (cytospin) RNA-ISH technique that is 5--10× more sensitive at assigning cell-type-specific expression patterns than scRNA-seq ([@bib107]) ([Figure 4](#fig4){ref-type="fig"}E). This technique identified ACE2 expression in ∼20% of interrogated cells versus ∼5% by scRNA-seq ([Figure 4](#fig4){ref-type="fig"}F). These studies identified the forkhead box J1 (FOXJ1)-defined ciliated cell as the most frequent cell type in nasal scrapes ([Figure S4](#figs4){ref-type="fig"} B) and that the percentage of ciliated cells expressing ACE2 was higher in the nose than in bronchi ([Figure 4](#fig4){ref-type="fig"}G). ACE2^+^- and MUC5B^+^-defined secretory ("club") cells were less frequent and expressed less ACE2 than ciliated cells in each airway region ([Figures 4](#fig4){ref-type="fig"}H and 4I). Both cell types in each region exhibited considerable variability in ACE2 expression ([Figures 4](#fig4){ref-type="fig"}H and 4I). Studies of nasal submucosal glands exhibited few or no detectable ACE2^+^ glandular cells ([Figure S4](#figs4){ref-type="fig"}C). Finally, application of this technique to freshly excised distal lung digests revealed expression of ACE2 in a fraction of AT2 cells ([Figure 4](#fig4){ref-type="fig"}Evi). ACE2 was detected in *HOPX* ^+^ cells, which in humans can be AT1 or AT2 cells ([Figure 4](#fig4){ref-type="fig"}Evii) ([@bib63]).Figure S4Additional data of SARS-CoV and SARS-CoV-2 infected primary human cells, related to [Figure 6](#fig6){ref-type="fig"}(A) Representative whole-mount extended focus views of icSARS-CoV-2-GFP-infected (i) HNE and LAE cell cultures. Red = filamentous actin (phalloidin), White = α-tubulin (multiciliated cells), Blue = nuclei (Hoechst 33342). Green = GFP (left). Green = SARS-CoV-2 Nucleocapsid (right). Yellow = MUC5AC (left). Yellow = MUC5B (right); (ii) LAE and SAE cell cultures. Yellow = filamentous actin (phalloidin), White = α-tubulin (multiciliated cells), Blue = nuclei (Hoechst 33342). Green = GFP (virus). Red = CCSP. Scale bars, 50 μm.(B) Merged of GFP and bright field mages taken from AT1 and AT2 cells infected with icSARS-CoV-2-GFP at 48 h. The AT-1 cells are present inside the enclosed areas. Bar = 100 μm.(C) GFP signals of icSARS2-GFP-infected HNEs collected from five different donors at 72 hpi, MOI = 3.(D) (i) Fluorescent signals of the two viruses in LAE (ii) Growth curves of three SARS-CoV-2 viruses in LAE from the same donor. Scale bar, 200 μm. (iii) Growth curves of two SARS-Urbani viruses in LAE. Data are presented in mean ± SD. All the infections in this figure were in MOI = 0.5.

Pre-existing pulmonary disease and ACE2 and TMPRSS2 expression {#sec2.5}
--------------------------------------------------------------

Suppurative muco-obstructive lung diseases, e.g., cystic fibrosis (CF) and non-CF bronchiectasis (NCFB), are characterized by airway mucus accumulation and neutrophilic inflammation and are reported to be at increased risk for severe SARS-CoV-2 infections ([@bib10], [@bib15]). To test whether dysregulation of ACE2 expression is a feature of CF, we performed RNA-ISH studies in excised CF lungs and revealed a striking upregulation of ACE2 and TMPRSS2 expression in CF airways ([Figure 5](#fig5){ref-type="fig"} A).Figure 5Inflammatory cytokines alter *ACE2* and *TMPRSS2* expression(A) RNA-ISH images demonstrating regional distribution of *ACE2* and *TMPRSS2* mRNA localization in normal and CF human airways. Scale bars, 20 μm. Images were obtained from four different airway regions from one normal or CF subject as representative of N = 6 normal or CF subjects studied.(B) mRNA expression of *ACE2* and *TMPRSS2* measured by Taqman assay after inflammatory cytokine challenge in primary human large airway epithelial cells. Shown in (i) is IL-1β (10 ng/mL, 7 days, N = 8), in (ii) is IFN-β (10 ng/mL, 3 days, N = 4 donors, 2--3 cultures per donor), and in iii is IL-13 (10 ng/mL, 7 days, N = 8). Wilcoxon matched pairs signed rank test was used for comparison between control and cytokine treatment groups. Histobars and error bars represent mean ± SD. Different symbol colors indicate results from different individual donors.

To gain insight into pathways that might contribute to dysregulation of ACE2 expression in CF lungs, we tested the effects of selected cytokines on ACE2 expression in large airway epithelial (LAE) cultures. Interleukin-1β (IL-1β), the dominant pro-mucin secretory cytokine in CF and NCFB secretions ([@bib17]), upregulated ACE2, but not TMPRSS2 ([Figure 5](#fig5){ref-type="fig"}Bi). Because CF subjects experience recurrent virus-driven exacerbations, we tested the effect of interferon-β (IFN-β) on ACE2 expression. ACE2 expression was significantly increased, whereas TMPRSS2 expression decreased, by IFN-β ([Figure 5](#fig5){ref-type="fig"}Bii). In contrast, IL-13, a cytokine associated with Th2-high asthma, inhibited ACE2 expression ([Figure 5](#fig5){ref-type="fig"}Biii).

SARS-CoV-2 infectivity specific to the respiratory tract region {#sec2.6}
---------------------------------------------------------------

To test the relationship between ACE2 entry receptor expression and SARS-CoV-2 infection, we inoculated primary epithelial cultures from the human nasal epithelia (human nasal epithelial cells \[HNE\], n = 9 donors), large airway (bronchi and large airway epithelial cells (LAE), n = 7 donors), lower airway (bronchiolar and small airway epithelial cells \[SAE\], n = 3 donors), nasal submucosal glands (n = 2 donors), type II- and type I-like pneumocytes (AT2/AT1-like) (n = 3 donors), microvascular endothelial cells (MVE) (n = 2 donors), and fibroblasts (FBs) (n = 2 donors), and an immortalized nasal cell line (UNCNN2TS) with icSARS-CoV-2-GFP reporter virus. We observed GFP signals and detected viral titers in HNE, LAE, SAE, AT2-like, and AT1-like cell cultures ([Figure 6](#fig6){ref-type="fig"} A). In contrast, nasal submucosal gland, UNCNN2TS, MVE, or FB cells were not susceptible, as evidenced by no GFP signals or detectable infectious titers of progeny viruses (not shown).Figure 6Replication of SARS-CoV-2 in primary human respiratory cells(A) Representative GFP signals in icSARS-CoV-2-GFP-infected HNE, LAE, SAE, AT2-like, and AT1-like cultures at 48 h. Scale bar, 80.(B) Growth curves of icSARS-CoV-2-GFP in (i) HNE, n = 9 donors; (ii) LAE, n = 7 donors; (iii) SAE, n = 3 donors; (iv) AT1-like (empty symbols) and AT2-like (filled symbols) cells, n = 3 donors per cell type. Cells from female and male donors are labeled in pink and blue, respectively. Triplicated viral infections under MOI of 3 or 0.5 are shown in solid and dotted lines, respectively. In (v) is a comparison of the highest titers of individual culture among cell types and in (vi) is a comparison of individual titers in HNE and LAE at different time points.(C) Representative whole-mount extended focus views of icSARS-CoV-2-GFP-infected HNE and LAE cell cultures. Color coding is as follows: red, filamentous actin (phalloidin); white, α-tubulin (multiciliated cells); green, GFP (virus); blue, nuclei (Hoechst 33342); yellow, MUC5B (left) and MUC5AC (right). An arrow represents viral-infected α-tubulin^+^ (ciliated) and MUC5B^+^ (secretory) transitional HNEs. Scale bars, 50 μm.(D) Shown in (i) is the variability of GFP and cilia signals in icSARS-CoV-2-GFP-infected LAE cultures collected from five different donors at 72 hours after infection, scale bar, 200 μm. Shown in (ii) is the quantification of ciliated area in the LAE cultures.(E) Growth curves of icSARS-CoV-2-GFP infected in LAE and SAE collected form the same donor. Cultures were infected with SARS-CoV-2 clinical isolate (i), WT (ii), and GFP (iii) with MOI of 0.5. Data are presented in mean ± SD.See also [Figure S4](#figs4){ref-type="fig"}.

We measured the relative infectivity of the SARS-CoV-2 GFP virus in primary cells on the basis of the average peak titers and observed that infectivity exhibited the same pattern as the ACE2 expression amounts from the upper to lower respiratory tract ([Figures 6](#fig6){ref-type="fig"}Bi--6Biv). The icSARS-CoV-2-GFP virus replicated efficiently in the HNE and LAE, and peak viral titers were significantly higher than the titers in SAE, AT2-like, and AT1-like cultures ([Figure 6](#fig6){ref-type="fig"}Bv). Although the viral peak titers were similar, the icSARS-CoV-2-GFP infection in HNE culture resulted in significantly higher titers than LAE at 24 h, 48 h, and 96 h after infection, suggesting more robust replication in the primary nasal cells ([Figure 6](#fig6){ref-type="fig"}Bvi). Collectively, these data indicate that virus infectivity or replication efficiency varies markedly from proximal airway to alveolar respiratory regions.

We utilized whole-mount immunohistochemistry of HNE and LAE cultures to identify cell types infected by SARS-CoV-2 ([Figures 6](#fig6){ref-type="fig"}C and [S4](#figs4){ref-type="fig"}A). The ciliated cell was routinely infected and extruded. In contrast, the other major cell type facing the airway lumen, i.e., the MUC5B^+^ club cell, was not infected, nor was the MUC5AC^+^ metaplastic goblet cell. We did note a cell type co-expressing the ciliated cell marker tubulin, and MUC5B was rarely infected in the HNE, a finding consistent with infection of a secretory (club) cell transitioning to a ciliated cell phenotype.

There is debate whether AT2 and/or AT1 cells express sufficient ACE2 to mediate infection and whether AT2, AT1, or both cell types are infectable. Previous studies reported 2003 SARS-CoV infects AT2 but not AT1 pneumocytes ([@bib60]). To focus on the relative infectivity by SARS-CoV-2 for AT2 versus AT1 cells, we tested standard AT2-AT1 cell cultures and a novel cell culture approach that well preserves AT2 and AT1 cell populations over the infection or GFP expression interval. As shown in [Figures 6](#fig6){ref-type="fig"}A and [S4](#figs4){ref-type="fig"}B, AT2 cells appeared to be preferentially infected.

SARS-CoV-2 infectivity specific to the respiratory tract region {#sec2.7}
---------------------------------------------------------------

We next investigated three other aspects of SARS-CoV-2 infection of human airway epithelia. First, the variability of infectivity among HNE and LAE cultures from multiple donors was characterized. Although all nine HNE and seven LAE were infected by icSARS-CoV-2-GFP, we observed marked variability in GFP signals per culture surface area and viral growth curves. LAE cultures exhibited higher variability in susceptible cells than the HNE cultures at 72 hours after infection ([Figures 6](#fig6){ref-type="fig"}A, 6B, 6D and [S4](#figs4){ref-type="fig"}C). We quantitated ciliated cell numbers in five LAE cultures, and we noted no correlation between susceptibility and ciliated cell percentages ([Figure 6](#fig6){ref-type="fig"}Dii).

Second, to further characterize the infectivity of LAE versus SAE, we compared replication rates of three SARS-CoV-2 viruses in LAE and SAE cultures from the same donor. All three viruses replicated more slowly in SAE than LAE cells. The GFP virus replicated modestly less effectively than the clinical isolate or WT virus in the two regions ([Figure 6](#fig6){ref-type="fig"}E). This observation differs from the equivalent replication noted in the Vero-E6 cells ([Figures 2](#fig2){ref-type="fig"}A and 2B), suggesting an intact ORF7 gene contributes to SARS-CoV-2 replication, and perhaps virulence, in human tissues.

Third, we compared the replication of SARS-CoV and SARS-CoV-2 in LAE cells. SARS-Urbani WT and GFP viruses, in parallel with the three SARS-CoV-2 viruses, were administered to LAE cultures from the same donor. GFP signals were detected in LAE cultures for both viruses, but the SARS-CoV-2-GFP exhibited delayed and less-intense signals than did SARS-CoV-Urbani-GFP ([Figure S4](#figs4){ref-type="fig"}D). This phenotype is consistent with the growth curve in which a lower titer of SARS-CoV-2 was recorded at 24 h.

SARS-CoV-2 infection in COVID-19 autopsy lungs {#sec2.8}
----------------------------------------------

We utilized RNA-ISH and immunohistochemistry (RNA-ISH/IHC) to localize virus in four lungs from SARS-CoV-2-infected deceased subjects ([Table S1](#mmc1){ref-type="supplementary-material"}). Multiple observations at different length scales were notable. First, at the macroscopic level, the infection appeared patchy, segmental, and peripheral ([Figures 7](#fig7){ref-type="fig"} A and [S5](#figs5){ref-type="fig"} A). These characteristics are consistent with an aspiration distribution of an infectious inoculum. Second, ciliated cells within the superficial epithelia lining proximal airway surfaces, particularly the trachea, were infected ([Figures 7](#fig7){ref-type="fig"}B and [S5](#figs5){ref-type="fig"}B). As observed *in vitro*, MUC5B^+^ club and MUC5AC^+^ goblet cells were not infected *in vivo*. Third, the submucosal glands that populate the large airway regions of the lung were not infected ([Figure S5](#figs5){ref-type="fig"}C). Fourth, alveolar cells were also infected. RNA *in situ* and IHC co-localization of an AT2 cell marker, SPC (*SFTPC*), and AT1 cell marker (AGER) with SARS-CoV-2 indicated that AT2 cells and AT1 cells (or AT2 cells that had transitioned to AT1 cells) were infected ([Figures 7](#fig7){ref-type="fig"}C and [S5](#figs5){ref-type="fig"}D).Figure 7Characterization of cell types for SARS-CoV-2 infection in SARS-CoV-2 autopsy lungs(A) Sections from an autopsy lung with SARS-CoV-2 infection were stained by hematoxylin and eosin (i) and probed for SARS-CoV-2 by RNA-ISH (ii--iv). A SARS-CoV-2 sense probe (ii) was used. Scale bars, 1 mm.(B) The trachea from a SARS-CoV-2 autopsy was probed for SARS-CoV-2 by RNA ISH. Shown in (i) is a colorimetric detection of SARS-CoV-2 (red) showing infection of surface epithelium. Shown in (ii--iv) is the co-localization of SARS-CoV-2 (red) with cell-type-specific markers (green) determined by dual-immunofluorescent staining (ii, acetylated α-tubulin cilia marker; iii, MUC5B secretory cell marker; and iv, MUC5AC mucous (goblet)-cell marker). Scale bars, 10 μm.(C) Co-localization of SARS-CoV-2 with alveolar cell-type-specific markers in the alveolar space from a SARS-CoV-2 autopsy. Shown in (i) is the dual color-fluorescent RNA-ISH co-localization of SARS-CoV-2 (green) with alveolar type II cell marker *SFTPC* (red). Shown in (ii) is the dual-immunofluorescent co-localization of SARS-CoV-2 (green) with alveolar type I cell marker AGER (magenta). Scale bars, 20 μm.(D) Mucin expression in SARS-CoV-2 autopsy lung. Shown in (i) is the AB-PAS (blue to purple) stain for complex carbohydrate (mucin), in (ii) is MUC5B immunohistochemistry, in (iii--v) is the dual-immunofluorescent staining for MUC5B (green) and MUC5AC (red) in the large airway (iv) and the alveoli (v). Abbreviation is as follows: SM, submucosal grand. Scale bars, 2mm (i--iii) and 200 μm (iv and v).See also [Figure S5](#figs5){ref-type="fig"}.Figure S5SARS-CoV-2 infection in SARS-CoV-2 autopsy lungs, related to [Figure 7](#fig7){ref-type="fig"}(A) Sections from of a second region of an autopsy lung with SARS-CoV-2 infection were stained by hematoxylin and eosin (H&E) (i) and probed for SARS-CoV-2 by RNA *in situ* hybridization (ISH) (ii, iii, and iv). Related to [Figure 7](#fig7){ref-type="fig"}A.(B) Frequency of acetylated alpha tubulin, MUC5AC, or MUC5B colocalization with SARS-CoV-2 positive cells in the trachea from a SARS-CoV-2 autopsy. A total of 200 randomly selected SARS-CoV-2 positive cells were analyzed for each dual staining condition. Related to [Figure 7](#fig7){ref-type="fig"}B ii, iii, iv.(C) Absence of SARS-CoV-2 infection in submucosal glands (SMG). (i-ii) H&E staining (i) and RNA-ISH (ii) for SARS-CoV-2 (red) in a large cartilaginous airway of one autopsy lung. SARS-CoV-2 is only present in the surface epithelium near the lumen, not in SMG. (iii-iv) H&E (iii) and dual-immunofluorescence staining using acetylated alpha tubulin (red) and anti-SARS-CoV-2 rabbit polyclonal antibody (green) (iv) from the trachea of a separate autopsy. Related to [Figure 7](#fig7){ref-type="fig"}B and [S5](#figs5){ref-type="fig"}Di.(D) Regional distribution of SARS-CoV-2 RNA from trachea to alveoli identified by RNA-ISH in one SARS-2-CoV autopsy lung (in i and ii, viral staining is red; in iii, viral staining is turquoise). RNA-ISH dual color images demonstrate SARS-CoV-2 RNA and *SFTPC* mRNA (alveolar type 2 cell marker) localization in alveoli of a SARS-CoV-2 autopsy lung. SARS-CoV-2 (turquoise) was identified in a *SFTPC* (red)-positive (iii, arrow) and a *SFTPC*-negative cell (iv, arrowhead); Scale bars, 2mm (A); 100 μm (C); 20 μm (D).

During the routine Alcian Blue Periodic Acid Schiff (AB-PA) staining that detects mucins or mucin-like carbohydrates in SARS-CoV-2-infected autopsy lungs, we noted faint AB-PAS staining in the peripheral lung, i.e., the alveolar region in some lungs ([Figures 7](#fig7){ref-type="fig"}D). Because aberrant mucin secretion and accumulation is a feature of parenchymal diseases that can progress to fibrosis, the AB-PAS material was characterized in more detail ([Figures 7](#fig7){ref-type="fig"}Dii--7Dv). IHC studies suggested that this material in large airways was a mixture of the secreted mucins MUC5B and MUC5AC ([Figure 7](#fig7){ref-type="fig"}Div). In the alveolar parenchymal region, MUC5B alone was detected and was enriched in the peripheral subpleural area, as often observed in idiopathic pulmonary fibrosis (IPF) ([Figure 7](#fig7){ref-type="fig"}Dv) ([@bib26]). Note, in none of the autopsy lungs studied was mechanical ventilation employed and the lung in graphics A and D of [Figure 7](#fig7){ref-type="fig"} was immersion fixed. These observations, coupled to the observation that MUC5AC was not detected in the peripheral region, makes it unlikely that MUC5B selectively was mechanically spread from central to peripheral lung zones.

Discussion {#sec3}
==========

We generated a SARS-CoV-2 reverse genetics system; characterized virus RNA transcription profiles; evaluated the effect of ectopically expressed proteases on virus growth; and used reporter viruses to characterize virus tropisms, *ex vivo* replication, and to develop a high-throughput neutralizing assay. These reagents were utilized to explore aspects of early infectivity and disease pathogenesis relevant to SARS-CoV-2 respiratory infections.

Our single-cell RNA-ISH technology extended the description of ACE2 in respiratory epithelia on the basis of scRNA-seq data ([@bib81]). Single-cell RNA-ISH detected ∼20% of upper respiratory cells expressing ACE2 versus ∼4% for scRNA-seq ([Figure 4](#fig4){ref-type="fig"}F). Most of the RNA-ISH-detected ACE2-expressing cells were ciliated cells, not normal MUC5B^+^ secretory (club) cells or goblet cells. Notably, the nose contained the highest percentage of ACE2-expressing ciliated cells in the proximal airways ([Figure 4](#fig4){ref-type="fig"}G). The higher nasal ACE2 expression-level findings were confirmed by qPCR data comparing nasal to bronchial airway epithelia. qPCR data also revealed that ACE2 amounts further waned in the more distal bronchiolar and alveolar regions. Importantly, these ACE2 expression patterns were paralleled by high SARS-CoV-2 infectivity of nasal epithelium with a gradient in infectivity characterized by a marked reduction in the distal lung (bronchioles and alveoli) ([Figures 6](#fig6){ref-type="fig"}A and 6B).

Multiple aspects of the variability in SARS-CoV-2 infection of respiratory epithelia were notable in these studies. First, significant donor variations in virus infectivity and replication efficiency were observed. Notably, the variability was less in the nose than lower airways. The reason(s) for the differences in lower airway susceptibility are important but remain unclear ([@bib18]). We identified variations in ACE2 receptor expression ([Figures 4](#fig4){ref-type="fig"}A--4D) but not numbers of ciliated cells as potential variables ([Figure 6](#fig6){ref-type="fig"}D). Second, variation in infectivity of a single cell type, i.e., the ciliated cell, was noted with only a fraction of ciliated cells having access to virus infected at 72 h ([Figure 6](#fig6){ref-type="fig"}A). Third, the dominant secretory cell, i.e., the MUC5B^+^ club cell, was not infected *in vitro* or *in vivo*, despite detectable ACE2 and TMPRSS2 expression ([Figures 4](#fig4){ref-type="fig"}G-4I). Collectively, these data suggest that measurements of ACE2 and TMPRSS2 expression do not fully describe cell infectivity and that a description of other variables that mediate susceptibility to infection, including the innate immune system(s), is needed ([@bib55]).

The ACE2 receptor gradient in the normal lung raised questions focused on the initial sites of respiratory tract virus infection, the mechanisms that seed infection into the deep lung, and the virus-host interaction networks that attenuate or augment intra-regional virus growth in the lung to produce severe disease, especially in vulnerable patients experiencing chronic lung or inflammatory diseases ([@bib36], [@bib49]).

We speculate that nasal surfaces might be the dominant initial site for SARS-CoV-2 respiratory tract infection ([@bib90]). First, SARS-CoV-2 RNA has been detected in aerosol particles in the range of aerodynamic sizes exhaled during normal tidal breathing ([@bib50], [@bib67]). Aerosol deposition and fomite mechanical delivery deposition modeling suggest that aerosols containing virus inhaled by naive subjects achieve the highest density of deposition, i.e., highest MOI per unit surface area, in the nose ([@bib9], [@bib27], [@bib82]). Second, the relatively high ACE2 expression in nasal specimens and the parallel high infectivity of the HNE cultures suggests the nasal cavity is a fertile site for early SARS-CoV-2 infection. Nasal infection likely is dominated by ciliated cells in the superficial epithelium, not nasal submucosal glands. Third, the nose is exposed to high but variable loads of environmental agents, producing a spectrum of innate defense responses. Hence, a portion of the variability of the clinical syndrome of COVID-19 might be affected by environmentally driven variance of nasal infectivity ([@bib94]).

Another aspect of the variability of the COVID-19 syndrome is the variable incidence and severity of lower lung disease. It is unlikely SARS-CoV-2 is transmitted to the lung by hematogenous spread, as demonstrated by the absence of infection of MVE cells and by previous reports that indicate airway cultures are difficult to infect from the basolateral surface ([@bib78], [@bib90]). Theoretically, infection could be transmitted directly to lower lung surfaces by microaerosol inhalation with deposition on and infection of alveolar surfaces mediated in part by the high ACE2 binding affinity reported for SARS-CoV-2 ([@bib77], [@bib91]). However, given the low amounts of ACE2 expression in alveolar cells in health, the correlated poor infectivity *in vitro*, and the absence of a homogeneous pattern radiographically, the importance of this route remains unclear ([@bib74]).

In contrast, it is well-known that an oral-lung aspiration axis is a key contributor to many lower airways infectious diseases ([@bib22], [@bib25], [@bib30], [@bib61], [@bib68]). Nasal secretions are swept from the nasal surface rostrally by mucociliary clearance and accumulate in the oral cavity at a rate of ∼0.5 mL/h where they are admixed with oropharyngeal or tonsillar fluid ([@bib24], [@bib66]). Especially at night, it is predicted that a bolus of relatively high titer virus is aspirated into the deep lung, either via microaspiration or as part of gastro-esophageal reflex-associated aspiration, sufficient to exceed the threshold PFU/unit surface area needed to initiate infection ([@bib4], [@bib33], [@bib39]). Note, our data that tracheas exhibited significant viral infection *in vivo* suggest that small-volume microaspiration could also seed this site. Tracheal-produced virus could then also accumulate in the oropharynx via mucus clearance for subsequent aspiration into the deep lung ([@bib69]). Oropharyngeal aspirates also contain enzymes and/or inflammatory mediators that might condition alveolar cells for infection. Aspiration of SARS-CoV-2 into the lung is consistent with the patchy, bibasilar infiltrates observed by chest CT in COVID-19 ([@bib96]). Notably, robust microaspiration and gastro-esophageal aspiration are observed frequently in subjects who are at risk for more severe COVID-19 lower respiratory disease, e.g., older, diabetic, and obese subjects ([@bib64], [@bib68]). Finally, our autopsy studies demonstrated patchy, segmental or subsegmental disease, consistent with aspiration of virus into the lung from the oropharynx.

These speculations describing the early pathogenesis of SARS-CoV-2 upper and lower respiratory tract disease are consistent with recent clinical observations. The data from [@bib90] in COVID-19-positive subjects support the concept of early infection in the upper respiratory tract (0--5 d) followed by subsequent aspiration and infection of the lower lung. These authors focused on the oropharynx as a potential site of the early virus propagation. As noted above, however, a nasal-oropharyngeal axis also exists, which has two implications. First, the nasal surfaces could seed the oropharynx for infection. Second, it is likely that oropharyngeal secretions reflect a mixture of local secretions admixed with a robust contribution of nasal mucus and virus.

Animal model data are also compatible with the scenario of aspiration-induced focal SARS-CoV-2 lung disease. The data of [@bib71] noted focal lung disease after combined intranasal versus intratracheal dosing with SARS-CoV-2 in cynomolgus monkeys. Notably, other findings in this model phenocopied our observations of human disease, e.g., early nasal shedding of virus, infection of nasal ciliated cells, and infection of AT2 and likely AT1 cells. Perhaps more definitive data describing nasal cavity seeding of the lower lung by microaspiration emanate from the studies of [@bib70]. These investigators demonstrated in ferret models that genetically marked virus delivered to the nasal cavity more efficiently transmitted infection to the lower lungs than a virus with a distinct genetic marker delivered directly into the lungs.

In addition to identifying possible microaspiration risk factors associated with COVID-19 disease severity in the elderly, diabetic, and obese, our studies provide insights into variables that control disease severity in subjects at risk because of pre-existing pulmonary disease ([@bib49], [@bib73]). For example, ACE2 expression was increased in the lungs of CF patients excised at transplantation. A major cytokine that produces the muco-inflammatory CF airways environment, IL-1β, was associated *in vitro* with increased ACE2 expression ([@bib17]). The clinical outcome of increased ACE2 expression in CF is not yet known. The simple prediction is that increased ACE2 expression might be associated with more frequent or severe SARS-CoV-2 disease in CF populations. However, increased ACE2 expression is reported to be associated with improved lung function by negatively regulating ACE and the angiotensin II and the angiotensin II type 1a receptor (AT1a) in models of alveolar damage (pulmonary edema) and bacterial infection ([@bib40], [@bib42], [@bib43], [@bib47], [@bib79]). Consequently, CF subjects might exhibit reduced severity of disease once acquired. Data describing outcomes of COVID-19 in the CF populations should emerge soon ([@bib19]).

Our autopsy studies also provide early insights into the variable nature of the severity and pathogenesis related to post-COVID-19 lung health or function ([@bib6], [@bib46], [@bib51]). Our study has identified another feature of COVID-19, i.e., the accumulation of apparently aberrantly secreted MUC5B in the alveolar region. Accumulation of MUC5B in the peripheral (alveolar) lung is characteristic of subjects who develop IPF, and polymorphisms in the MUC5B promoter associated with IPF have been reported ([@bib26]). Future studies of the long-term natural history of SARS-CoV-2 survivors, in combination with studies delineating the cell types responsible for MUC5B secretion (AT2 versus airway cells) and genetics, e.g., MUC5B polymorphisms, might aid in understanding the long-term favorable versus fibrotic outcomes of COVID-19 disease ([@bib16], [@bib72]).

Our study also provides a SARS-CoV-2 infectious full-length cDNA clone for the field. Several strategies have been developed to construct stable coronavirus molecular clones, including the bacterial artificial chromosome (BAC) ([@bib3], [@bib34]) and vaccinia viral vector systems ([@bib14]). In contrast, our *in vitro* ligation method solves the stability issue by splitting unstable regions and cloning the fragmented genome into separate vectors, obviating the presence of a full-length genome ([@bib99]). Our *in vitro* ligation strategy has generated reverse genetic systems for at least 13 human and animal coronaviruses and produced hundreds of mutant recombinant viruses ([@bib8], [@bib56], [@bib76], [@bib95], [@bib100]). In contrast to other reports ([@bib83]), reporter recombinant SARS-CoV-2 viruses generated herein replicated to normal WT amounts in continuous cell lines, allowing for robust *ex vivo* studies in primary cultures.

Using this infectious clone, we generated a high-throughput luciferase reporter SARS-CoV-2 assay for evaluation of viral nAbs. In line with previous reports ([@bib85], [@bib91]), our data show that several SARS-CoV RBD-binding nAbs fail to neutralize SARS-CoV-2, suggesting distant antigenicity within the RBD domains between the two viruses. Although more samples are needed, early convalescent sera demonstrated ∼1.5 log variation in neutralizing titers at ∼day 30 after infection, demonstrating a need to fully understand the kinetics, magnitude, and durability of the neutralizing antibody response after a primary SARS-CoV-2 infection. The detection of low-level SARS-CoV-2 cross-neutralizing antibodies in 2003 SARS-CoV serum samples is consistent with recent studies ([@bib37], [@bib86]), suggesting that existence of common neutralizing epitopes between the two CoVs. Interestingly, convalescent COVID-19 sera failed to cross-neutralize SARS-CoV *in vitro*, suggesting cross-neutralizing antibodies might be rare after SARS-CoV-2 infection. The location of these epitopes is unknown. The nLuc recombinant viruses described herein will be powerful reagents for defining the antigenic relationships between the Sarbocoviruses, the kinetics and durability of neutralizing antibodies after natural infection, and the breadth of therapeutic neutralizing antibodies and vaccine countermeasures ([@bib87]).

In summary, our studies have quantitated differences in ACE2 receptor expression and SARS-CoV-2 infectivity in the nose (high) versus the peripheral lung (low). These studies should provide valuable reference data for future animal model development and expand the pool of tissues, e.g., nasal, for future study of disease pathogenesis and therapy. Although speculative, if the nasal cavity is the initial site mediating seeding of the lung via aspiration, these studies argue for the widespread use of masks to prevent aerosol, large droplet, and/or mechanical exposure to the nasal passages. Complementary therapeutic strategies that reduce viral titer in the nose early in the disease, e.g., nasal lavages, topical antivirals, or immune modulation, might be beneficial. Finally, our studies provide key reagents and strategies to identify type-specific and highly conserved neutralizing antibodies that can be assessed most easily in the nasal cavity as well as in the blood and lower airway secretions.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal human MUC5BSanta CruzRRID: [AB_2282256](nif-antibody:AB_2282256){#intref0010}Mouse monoclonal human MUC5ACInvitrogenRRID: [AB_10978001](nif-antibody:AB_10978001){#intref0015}Rabbit polyclonal SARS coronavirus nucleocapsidInvitrogenRRID: [AB_1087200](nif-antibody:AB_1087200){#intref0020}Mouse monoclonal anti-acetylated tubulinSigma-AldrichRRID: [AB_609894](nif-antibody:AB_609894){#intref0025}Rabbit polyclonal prosurfactant protein CSigma-AldrichRRID: [AB_91588](nif-antibody:AB_91588){#intref0030}Goat polyclonal AGERR&D SystemsRRID: [AB_354628](nif-antibody:AB_354628){#intref0035}Rat monoclonal anti-tubulinMilliporeRRID: [AB_2210391](nif-antibody:AB_2210391){#intref0040}Goat polyclonal anti-GFPAbCamRRID: [AB_305643](nif-antibody:AB_305643){#intref0045}Rabbit polyclonal anti-GFPAbCamRRID: [AB_305564](nif-antibody:AB_305564){#intref0050}Alexa Fluor phalloidin 647InvitrogenRRID: [AB_2620155](nif-antibody:AB_2620155){#intref0055}Alexa Fluor phalloidin 555InvitrogenCat\#A34055Hoechst 33342InvitrogenCat\#H3570Goat anti-CCSPSigma-AldrichCat\#ABS1673Alexa Fluor 488-AffiniPure Donkey Anti-Goat IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot) antibodyJackson ImmunoResearchRRID: [AB_2336933](nif-antibody:AB_2336933){#intref0060}Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 555InvitrogenRRID: [AB_162543](nif-antibody:AB_162543){#intref0065}Donkey anti-Rat IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594InvitrogenRRID: [AB_2535795](nif-antibody:AB_2535795){#intref0070}Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647InvitrogenRRID: [AB_162542](nif-antibody:AB_162542){#intref0075}Alexa Fluor 488-AffiniPure Donkey Anti-Rabbit IgG (H+L) antibodyJackson ImmunoResearchRRID: [AB_2313584](nif-antibody:AB_2313584){#intref0080}Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 555InvitrogenRRID: [AB_2536180](nif-antibody:AB_2536180){#intref0085}Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647Thermo Fisher ScientificRRID: [AB_2535864](nif-antibody:AB_2535864){#intref0090}S230UNC protein core facilityN/AS230.15UNC protein core facilityN/AS227.14UNC protein core facilityN/AS227.9UNC protein core facilityN/AMERS-27UNC protein core facilityN/Am336UNC protein core facilityN/AEDE1-C10UNC protein core facilityN/Aanti-SARS-CoV N proteinInvitrogenCat\#PA1-41098**Bacterial and Virus Strains**SARS-CoV-2 WA1 isolateNatalie J. Thornburg, CDCGenBank: MT020880icSARS-CoV-2-WTThis paperGenBank: MT461669icSARS-CoV-2-GFPThis paperGenBank: MT461670icSARS-CoV-2-nLuc-GFPThis paperGenBank: MT461671**Biological Samples**Human nasal, tonsil, and lung samples from CF and non-CF subjectsMarsico Lung Institute, UNCSee [Table](#mmc1){ref-type="supplementary-material"} S1 for a list of donorsHuman nasal and lung samples from healthy volunteersNHLBISee [Table S1](#mmc1){ref-type="supplementary-material"} for a list of donorsHuman lung histology sections from COVID-19 subjectsUniversity of New Mexico, New York Presbyterian HospitalSee [STAR Methods](#sec4){ref-type="sec"}SARS patient serum samples (Toronto)University Health Network, MaRS Center, CanadaIRB\#:UHN REB 03-0250COVID-19 serum samplesUNC HospitalIRB\#:20-1141Mouse serum anti SARS-CoV-2 spikeThis paperN/AMouse serum anti SARS-CoV-2 nucleocapsidThis paperN/A**Chemicals, Peptides, and Recombinant Proteins**Recombinant human IL1β proteinR&D SystemsCat\#201-LB-005Recombinant human IL13 proteinR&D SystemsCat\#213-ILB-005Recombinant human IFNβ proteinR&D SystemsCat\#8499-IF-010HydrocortisoneSigmaCat\#H0888EGFInvitrogenCat\#PHG0313InsulinSigmaCat\#I5500Amphotericin BFisher ScientificCat\#BP264550GentamincinGIBCOCat\#15710-064Cholera toxinSigmaCat\#C8052Y-27632Enzo life ScienceCat\#ALX-270-333-M025TRIzol ReagentThermoFisherCat\#15596026**Critical Commercial Assays**Direct-zol RNA MiniprepZYMO ResearchCat\#R2051iScript™ Reverse Transcription Supermix for RT-qPCRBIO-RADCat\#1708840SsoAdvanced Universal Probes SupermixBIO-RADCat\#1725280RNAScope Multiplex Fluorescent Reagent Kit v2ACDCat\#323100RNAScope 2.5 HD Duplex Reagent KitACDCat\#322430RNAScope 2.5 HD Reagent Kit-REDACDCat\#322350RNAScope probe FOXJ1 (channel 2)ACDCat\#476351-C2RNAScope probe MUC5B (channel 2)ACDCat\#449888-C2RNAScope probe ACE2 (channel 1)ACDCat\#848151RNAScope probe ACE2 (channel 2)ACDCat\#848151-C2RNAScope probe TMPRSS2 (channel 1)ACDCat\#470341RNAScope probe SARS-CoV-2, S gene encoding the spike protein (channel 1)ACDCat\#848561RNAScope probe SARS-CoV-2, Antisense strand of the S gene (channel 1)ACDCat\#845701RNAScope probe SFTPC (channel 2)ACDCat\#452561-C2RNAScope probe HOPX (channel 1)ACDCat\#423001Vector® TrueVIEW® Autofluorescence Quenching KitVector LaboratoriesCat\#SP-8400Taqman probe TBPFisher ScientificCat\#Hs99999910_m1Taqman probe GAPDHFisher ScientificCat\#Hs02758991_g1Taqman probe ACE2Fisher ScientificCat\#Hs01085333_m1Taqman probe TMPRSS2Fisher ScientificCat\#Hs01122322_m1Nano-Glo Luciferase AssayPromegaCat\#N1130QIAprep Spin Mini-prep KitQIAGENCat\#27106ExpiFectamine 293 transfection kitThermoCat\#A14526NorthernMax-Gly KitInvitrogenCat\#AM1946QIAquick Gel Extraction kitQIAGENCat\#28706mMESSAGE mMACHINE T7 transcription kitThermoFisherCat\#AM1344Chemiluminescent Nucleic Acid Detection ModuleThermoFisherCat\#89880Oligotex mRNA Mini KitQIAGENCat\#70022**Deposited Data**icSARS-CoV-2 WT genomic sequenceGenBankMT461669icSARS-CoV-2-GFP genomic sequenceGenBankMT461670icSARS-CoV-2-nLuc-GFP genomic sequenceGenBankMT461671**Experimental Models: Cell Lines**Simian kidney VeroATCCCat\#CCL81Simian kidney Vero E6ATCCCat\#CRL1586LLC-MKATCCCat\#CCL-7UNCNN2TSMarsico Lung Institute, UNCN/APrimary nasal cellsMarsico Lung Institute, UNCN/AHuman bronchial epitheliumMarsico Lung Institute, UNCN/AHuman alveolar type II pneumocytesMarsico Lung Institute, UNCN/AHuman primary lung microvascular endothelial cellsMarsico Lung Institute, UNCN/AHuman primary lung fibroblastsMarsico Lung Institute, UNCN/A**Experimental Models: Organisms/Strains**Mouse: BALB/cJackson LabsCat\#000651**Oligonucleotides**Leader forward primer: 5′- GTTTATACCTTCCCAGGT\
AACAAACC −3′This paperN/AM gene reverse primer: 5′- AAGAAGCAATGAAGTA\
GCTGAGCC −3′This paperN/AN gene primer: 5′-GTAGAAATACCATCTTGGACT\
GAGATC −3′This paperN/ART-PCR primer: 5′-GCTTCTGGTAATCTATTACTAG\
ATAAACG-3′This paperN/ART-PCR primer: 5′- AAGACATCAGCATACTCCTG\
ATTAGG −3′This paperN/Abiotin-labeled oligomer: 5′- BiodT/GGCTCTGTTGGGA\
ATGTTTTGTATGCG/BiodT-3′This paperN/A**Recombinant DNA**7 plasmids of icSARS-CoV-2 WTThis paperN/A1 plasmid encoding icSARS-CoV-2-nLuc-GFP reporterThis paperN/A1 plasmid encoding icSARS-CoV-2-GFP reporterThis paperN/A**Software and Algorithms**QuantStudio 6 Flex SystemThermoFisher ScientificCat\#4485697QuantStudio Software v1.3ThermoFisher Scientific<https://thermofisher.com>GraphPad Prism 8GraphPad<https://graphpad.com>Olyvia V3.1.1Olympus<https://olympus-lifescience.com>Adobe PhotoshopAdobe<http://www.adobe.com/nl/products/photoshop.html>R version 3.5.1R Foundation<https://www.r-project.org/>**Other**T4 DNA LigaseNEBCat\#M0202SBsmBINEBCat\#R0580SacINEBCat\#R0156SPrimeSTAR GXL HiFi DNA polymeraseTaKaRaCat\#RF220Q
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### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ralph S. Baric (<rbaric@email.unc.edu>).

### Materials Availability {#sec4.2.2}

Material and reagents generated in this study will be made available upon installment of a material transfer agreement (MTA).

### Data and Code Availability {#sec4.2.3}

Genomic sequences of recombinant viruses icSARS-CoV-2-WT, icSARS-CoV-2-GFP and icSARS-CoV-2-nLuc-GFP, which were generated in this study, have been deposited to GenBank (Accession \# MT461669 to MT461671).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human Subjects {#sec4.3.1}

Excess surgical pathology tissues were obtained from the University of North Carolina (UNC) Tissue Procurement and Cell Culture Core under protocol \#03-1396 approved by the UNC Biomedical IRB. Informed consent was obtained from tissue donors or authorized representatives. Cystic fibrosis lung tissue was obtained from donors undergoing transplantation, while human lungs from previously healthy individuals unsuitable for transplantation were obtained from Carolina Donor Services (Durham, NC), the National Disease Research Interchange (Philadelphia, PA), or the International Institute for Advancement of Medicine (Edison, NJ). Upper airway tissues were obtained from subjects undergoing elective surgeries. Excised tissue specimens were dissected and fixed in 10% neutral buffered formalin for 48 h followed by paraffin-embedding. The paraffin blocks were cut to produce 5 μm serial sections for RNA-ISH and immunohistochemistry. For qRT-PCR for *ACE2* and *TMPRSS2* expression in nasal and bronchial epithelial cells, nasal and bronchial epithelial cells were obtained from matched healthy volunteers by nasal scraping and bronchoscopic brush-biopsy under the National Heart, Lung, and Blood Institute IRB-approved protocol \#07-H-0142. For single cell-RNA *in situ* hybridization (scRNA-ISH), human bronchial epithelial cells were obtained from the left main bronchus of healthy non-smoker volunteers by bronchoscopic brush-biopsy under the UNC Biomedical IRB-approved protocol \#91-0679. Nasal surface epithelial cells were isolated from the resected nasal tissues as previously described ([@bib28], [@bib62]). After the isolation of nasal surface epithelial cells, the remaining nasal tissues were micro-dissected to isolate submucosal glands under the light microscope. Donor demographics was shown in [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Tissue blocks or cut sections obtained from four COVID-19 autopsy lungs were obtained from Drs. Ross. E. Zumwalt (University of New Mexico) and Steven Salvatore and Alain Borczuk (New York Presbyterian Hospital). Donor demographics were described as below.

Donor 1. 40-year-old, male. Medical history: Diabetes mellitus. Clinical course: This donor had upper respiratory infection (URI) symptoms three days before he was found dead at home. No intubation was conducted. Postmortem testing of the lung was positive for SARS-CoV-2.

Donor 2. 64-year-old, male. Medical history: Diabetes mellitus, diabetic nephropathy, hepatitis C, heart failure, and coronary artery disease. Clinical course: This donor was transferred to ER because of fever and respiratory distress. Nasal swab was positive for SARS-CoV-2. He died five h after urgent care. No intubation was conducted.

Donor 3. 95-year-old, female. Medical history: Hypertension, hyperlipidemia, Alzheimer's disease. Clinical course: This donor was transferred to ER because of respiratory distress. Nasal swab was positive for SARS-CoV-2. She died 48 h after urgent care. No intubation was conducted.

Donor 4. 69-year-old, male. Medical history: acute myeloid leukemia, type 2 diabetes mellitus. Clinical course: This donor was admitted to the hospital because of respiratory distress eight days after initial URI symptoms and diagnosis of SARS-CoV-2. He died five days post admission. No intubation was conducted.

### Primary Cell Culture {#sec4.3.2}

Primary human nasal epithelial cells (HNE) were collected from healthy volunteers by curettage under UNC Biomedical IRB-approved protocols (\#11-1363 and \#98-1015) after informed consent as previously described ([@bib44], [@bib45]). Briefly, superficial scrape biopsies were harvested from the inferior nasal turbinates under direct vision through a 9 mm reusable polypropylene nasal speculum (Model 22009) on an operating otoscope with speculum (Model 21700). Both nostrils were scraped 5 times without anesthesia using a sterile, plastic nasal curette (Arlington Scientific). Nasal cells were expanded using the conditionally reprogrammed cell (CRC) method ([@bib31]) or in Pneumacult EX Plus media (Stem Cell Technologies) ([@bib80]) and then cultured on porous Transwell (Corning) supports in Pneumacult air liquid interface (ALI) media (Stem Cell Technologies). Human bronchial epithelial \[large airway epithelial (LAE)\] and bronchiolar \[small airway epithelial (SAE)\] cells, human alveolar type II pneumocytes (AT2), and human primary lung microvascular endothelial cells (MVE) and fibroblasts (FB) were isolated from freshly excised normal human lungs obtained from transplant donors with lungs unsuitable for transplant under IRB-approved protocol (\#03-1396), as previously described ([@bib28], [@bib62]).

### Cell Lines {#sec4.3.3}

Simian kidney cell lines Vero (ATCC \# CCL81), Vero E6 (ATCC \# CRL1586), and LLC-MK (ATCC\# CCL-7) were purchased from ATCC and preserved in our laboratory. The Vero-furin cell line was reported previously ([@bib105]). LLC-MK cells expressing TMPRSS2 were generated in our laboratory. A novel immortalized nasal cell line (UNCNN2TS) was created by lentiviral overexpression of Bmi-1 and hTERT ([@bib29]) in primary nasal cells, and subsequent lentiviral addition of SV40 T antigen (pBSSVD2005 was a gift from David Ron, Addgene plasmid \# 21826). UNCNN2T cells are grown and infected in EpiX media (Propagenix).

### Virus strains {#sec4.3.4}

Clinical SARS-CoV-2 isolate WA1 strain was provided by Dr. Natalie J. Thornburg at the U.S. Centers for Disease Control and Preventive (CDC). The virus was isolated from the first US COVID-19 patient identified in Washington state (GenBank Accession\#: MT020880). Recombinant CoVs icSARS-CoV-Urbani, icSARS-CoV-GFP, icSARS-CoV-nLuc and icMERS-CoV-nLuc were generated in our laboratory as described previously ([@bib76], [@bib100]). Briefly, the strategy to synthesize full-length cDNA clones for SARS-CoV-Urbani and MERS-CoV was identical to the method reported herein, but with different restriction sites and junctions. The GFP and nLuc reporters were inserted into the accessory ORF7a of the icSARS-CoV-Urbani clone, whereas the nLuc reporter gene was introduced into the accessory ORF5a of the icMERS-CoV clone. Virus stocks were propagated on Vero E6 cells in minimal essential medium containing 10% fetal bovine serum (HyClone) and supplemented with penicillin/kanamycin (Gibico). Virus plaques were visualized by neutral red staining at two days post-infection. The UNC Institutional Biosecurity Committee and the National Institute of Allergy and Infectious Disease (NIAID) have approved the SARS-CoV-2 molecular clone project. All viral infections were performed under biosafety level 3 (BSL-3) conditions at negative pressure, and Tyvek suits connected with personal powered-air purifying respirators.

### Human serum samples {#sec4.3.5}

SARS serum samples were obtained from SARS convalescent patients from University Health Network, MaRS Center, Toronto, Canada that had a confirmed SARS infection under IRB-approved protocol (\#UHN REB 03-0250). COVID-19 serum samples were also provided as coded material and were deemed "not human subject research" by the UNC School of Medicine Biomedical IRB (\#20-1141).

Method Details {#sec4.4}
--------------

### Primary human cell culture and infection {#sec4.4.1}

Nasal cells were expanded using the conditionally reprogrammed cell (CRC) method ([@bib31]) or in Pneumacult EX Plus media (Stem Cell Technologies) ([@bib80]) and then cultured on porous Transwell (Corning) supports in Pneumacult air liquid interface (ALI) media (Stem Cell Technologies). Human LAE and SAE cells were cultured as previously described ([@bib28], [@bib62]). Briefly, Isolated LAE and SAE cells were co-cultured with mitomycin-treated 3T3 J2 cells on collagen-coated tissue culture plastic dishes in DMEM media supplemented with 10 μM Y-27632 (Enzo Life Science). At 70%--90% confluence, LAE and SAE cells were passaged and sub-cultured for expansion. P2 LAE and SAE cells were transferred to human placental type IV collagen-coated, 0.4 μm pore size Millicell inserts (Millipore, PICM01250). The LAE and SAE cells were seeded at a density of 2.8 × 10^5^ cells/cm^2^ and cultured in UNC ALI media. Upon confluence, cells were maintained at an ALI by removing apical media and providing UNC ALI media to the basal compartment only. Medium was replaced in the basal compartment twice a week, and the apical surfaces were washed with PBS once a week. After 28 days, LAE and SAE cells were utilized for SARS-CoV-2 recombinant viruses infection. Human type II pneumocytes (AT2) were prepared and cultured on porous supports as previously described ([@bib11]). The AT2 cells are grown in DMEM with P/S and 10% FBS and switched to 4% FBS 24 h prior to infection. Cells were studied within three days and after five days, as they transdifferentiate into type I pneumocyte (AT1)-like cells. For serum-free and feeder-free AT2 cell cultures (mixed AT1/AT2 culture), human lung pieces (∼2 gm) were washed twice with PBS containing 1% Antibiotic-Antimycotic and cut into small pieces. Visible small airways and blood vessels were carefully removed to avoid clogging. Then samples were digested with 30 mL of enzyme mixture (collagenase type I: 1.68 mg/mL, dispase: 5U/mL, DNase: 10 U/mL) at 37°C for 45 min with rotation. The cells were filtered through a 100 μm strainer and rinsed with 15 mL PBS through the strainer. The supernatant was removed after centrifugation at 450x g for 10 min and the cell pellet was resuspended in red blood cell lysis buffer for five minutes, washed with DMEM/F12 containing 10% FBS and filtered through a 40 μm strainer. To purify human AT2 cells, approximately two million total lung cells were resuspended in SF medium and incubated with Human TruStain FcX (BioLegend) followed by incubation with HTII-280 antibody (Terrace Biotech). The cells were washed with PBS and then incubated with anti-mouse IgM microbeads. The cells were loaded into LS column (Miltenyi Biotec) and labeled cells collected magnetically. HTII-280^+^ human AT2 cells (1-3 × 10^3^) were resuspended in culture medium. Serum-free feeder free medium and AT2 differentiation medium will be described elsewhere (S.V. and PRT et al., currently under revision in Cell Stem Cell). Culture plates were coated with Cultrex reduced growth factor basement membrane extract, Type R1 and cultured for five days followed by changing medium to AT2 differentiation medium for additional five days.

Human primary lung microvascular endothelial cells (MVE) and fibroblasts (FB) were grown as previously described ([@bib76]). For MVE cells, peripheral lung tissue minus the pleura was minced, digested with dispase/elastase, and cells were grown in EGM-2 media plus FBS (Lonza). Two or three rounds of CD31 bead purification (Dynabeads; Life Technologies) resulted in \> 95% CD31-positive cells by flow cytometry that were used between passages 5 and 10. FBs were obtained by finely mincing distal human lung tissue and plating on scratched type 1/3 collagen-coated dishes in Dulbecco's modified Eagle medium with high glucose (DMEMH) media plus 10% FBS, antibiotics, and antimycotics. Cells were released using trypsin/EDTA and subcultured in DMEMH, 10% FBS and P/S. The subcultured cells were elongated, spindly and negative for CD31 and pan-cytokeratin by flow cytometry and immunofluorescence, respectively.

icSARS-CoV-2-GFP virus infections were performed using well differentiated air-liquid interface (ALI) cultures of five donor specimens of human nasal epithelial (HNE) and large airway epithelial (LAE) cells using an MOI of three. Small airway epithelial (SAE) cell ALI cultures were created as previously described ([@bib62]). Paired LAE / SAE cells were inoculated with a SARS-CoV-2 clinical isolate, icSARS-CoV-2-WT, and icSARS-CoV-2-GFP, as well as wild-type icSARS-CoV-Urbani and icSARS-CoV-GFP on LAE, using an MOI of 0.5 for each virus. Transwell-cultured primary cells were inoculated with 200ul of virus v*ia* the apical surface and allowed to incubate at 37°C for two h. Following incubation, virus was removed, and cells were washed twice with 500ul PBS. Cells were returned to 37°C for the remainder of the experiment and observed for fluorescent signal, when appropriate, every 12-24 h. 100ul PBS was added to the apical surface of each culture and allowed to incubate for 10 min at 37°C in order to obtain an apical wash sample, at time points for analysis of viral replication by plaque assay. At the last time point, cells were lysed with 500ul TRIzol reagent (Invitrogen) to obtain total final RNA for analysis.

#### Primary human bronchial epithelial cell culture and cytokines exposure {#sec4.4.1.1}

Primary human LAE cells from normal donors (obtained from donors without previously known pulmonary diseases) were cultured on the human placenta collagen IV (Sigma Cat\#C-7521) coated transwell (Corning Cat\#3460) under air-liquid interface (ALI) condition. The apical surface was washed with PBS, and ALI medium ([@bib29]) was replaced only in the basal compartment two-three times per week, and cells were cultured under ALI conditions for four weeks to allow full differentiation. Exposure with recombinant human cytokines was administrated started at the 5^th^ week after ALI culture. All recombinant human cytokines (IL1β at 10 ng/mL, IL13 at 10ng/mL, and IFNβ at 10ng/m of final concentration in ALI media) were added to basolateral side of ALI media, and media were changed after three days supplied with freshly diluted cytokines. Cells were collected at day five -- day seven for RNA isolation.

### Whole-mount immunostaining and imaging {#sec4.4.2}

Well-differentiated mock or icSARS-CoV-2-GFP-infected LAE ALI cultures were fixed twice for 10 min in 4% formaldehyde in PBS and washed and stored in PBS. The GFP signal was enhanced by staining with anti-GFP antibody (Abcam ab6556; 0.5 ug/mL), a Venezuelan equine encephalitis virus (VEEV)-like replicon particle-immunized mouse antiserum against SARS-CoV-2 N protein (1:4000 dilution) and polyclonal rabbit anti-SARS-CoV N protein (Invitrogen PA1-41098, 0.5 ug/mL) using species-specific secondary antibodies as previously described ([@bib32]). The cultures were also imaged for α-tubulin (Millipore MAB1864; 3ug/mL), MUC5AC (ThermoScientific 45M1; 4 ug/mL), MUC5B \[polyclonal rabbit against a MUC5B peptide (MAN5BII), 1:1000\] ([@bib84]), and CCSP (Sigma 07-623; 1:2000) as indicated. Filamentous actin was localized with phalloidin (Invitrogen A22287), and DNA with Hoechst 33342 (Invitrogen). An Olympus FV3000RS confocal microscope in Galvo scan mode was used to acquire 5-channel Z stacks by 2-phase sequential scan. Representative stacks were acquired with a 60X oil objective (xyz = 212um x 212um x ∼25um), and are shown as Z-projections or single-slice, XZ cross sections to distinguish individual cell features and to characterize the infected cell types. A 20X objective was used to acquire 2D, single-channel, apical snapshots of nine fields (636 um × 636 um; combined area = 3.64mm^2^), selected in evenly spaced grids across each sham infected donor culture, and ImageJ was used to measure the relative apical culture surface covered by multiciliated cells.

### Immunohistochemistry {#sec4.4.3}

Immunohistochemical staining was performed on COVID-19 autopsy lung sections according to a protocol as previously described ([@bib62]). Briefly, paraffin-embedded sections were baked at 60c°C for 2--4chours, and deparaffinized with xylene (2 changes × 5 min) and graded ethanol (100% 2 × 5 min, 95% 1 × 5 min, 70% 1 × 5 min). After rehydration, antigen retrieval was performed by boiling the slides in 0.1cM sodium citrate pH 6.0 (3 cycles with microwave settings: 100% power for 6.5cmin, 60% for 6cmin, and 60% for 6cmin, refilling the Coplin jars with distilled water after each cycle). After cooling and rinsing with distilled water, quenching of endogenous peroxidase was performed with 0.5% hydrogen peroxide in methanol for 15cmin, slides washed in PBS, and blocked with 4% normal donkey serum, for an h at RT. Primary antibody (MUC5AC: 45M1, 1:1000, MUC5B: H300, 1:1000, SARS-CoV-2 nucleocapsid: 1:500, Anti-SARS mouse antiserum: 1:4000, Acetylated-α-tubulin: 1:1000, AGER: 1:400) were diluted in 4% normal donkey serum in PBST and incubated over night at 4c°C. Mouse and rabbit gamma globulin was used as an isotype control at the same concentration as the primary antibody. Sections were washed in PBST and secondary antibodies (biotinylated donkey anti-rabbit IgG, at 1:200 dilution in 4% normal donkey serum in PBST for chromogenic DAB staining for MUC5B, Alexa Fluor 488 donkey anti-rabbit IgG, at 1:1000 dilution and Alexa Fluor 594 donkey anti-mouse IgG, at 1:1000 dilution for fluorescent staining) were applied for 60cmin at RT. After washing in PBST, the Vector® TrueVIEW Autofluorescence Quenching Kit (Vector laboratories) was used to reduce background staining, and glass coverslips were placed over tissue sections with the ProLong Gold Antifade Reagent with DAPI (Invitrogen) for fluorescent staining. For chromogenic DAB staining, slides were incubated with avidin-peroxidase complex according to the manufacturer's instructions (Vectastain kit, Vector laboratories), washed, incubated with the chromogenic substrate (Immpact Novared, Vector laboratories) and counterstained with Fast Red. Coverslipped slides were scanned and digitized using an Olympus VS120 whole slide scanner microscope with a 40X/60X 0.95 NA objective and Olympus confocal microscope with a 40X 0.6 NA or 60X 1.4 NA objective.

### Cell dissociation for single cell-RNA *in situ* hybridization (scRNA-ISH) {#sec4.4.4}

Fresh bronchoscopically brush-biopsied human main bronchial epithelial cells, nasal surface epithelial and submucosal gland cells isolated from the resected nasal tissues were incubated with Accutase solution for 30 min at 37°C. The Accutase-treated cells were centrifuged (450 g, 2 min, 4°C) and then incubated with 10 mL HBSS (Ca^+^, Mg^+^) buffer containing DNase I (0.1 mg/mL) (Roche \#10104159001) and collagenase IV (1 mg/mL) (GIBCO \#17104-019) for 10 min and 30 min for bronchial/nasal surface epithelial cell and nasal submucosal gland cell isolation, respectively at 37°C with intermittent agitation. Nasal submucosal glands were micro-dissected from the nasal tissues under microscopy. The tissues were centrifuged (450 g, 2 min, 4°C) and then incubated with 10 mL HBSS (Ca^+^, Mg^+^) buffer containing DNase I (0.1 mg/mL) and collagenase IV (1 mg/mL) for 30 min at 37°C with intermittent agitation followed by additional incubation with Trypsin-EDTA (Final concentration: 0.125%, GIBCO \#25200-056) for 20 min at 37°C. After incubation, enzymes were inactivated by adding 500 μL fetal bovine serum. Dissociated cells were filtered through a 40-μm cell strainer, centrifuged (450 g, 2 min, 4°C) and resuspended in PBS, adjusted to 10^5^ cells/mL. Cell viability was examined by trypan blue dye exclusion. Single cell suspension was cytocentrifuged (55 g, 4 min, StatSpin CytoFuge2, Beckman Coulter) and fixed in 10% NBF for 30 min at room temperature. The cytocentrifuged cells were washed with PBS three times and then dehydrated with graded ethanol (50% 1 min, 70% 1 min, 100% 1 min). The slides were stored in 100% ethanol at −20°C until future use for scRNA-ISH.

### RNA *in situ* hybridization {#sec4.4.5}

RNA-ISH was performed on cytocentrifuged single cells using the RNAscope Multiplex Fluorescent Assay v2, and on paraffin-embedded 5 μm tissue sections using the RNAscope 2.5 HD Reagent Kit and RNAscope 2.5 HD Duplex Reagent Kit according to the manufacturer's instructions (Advanced Cell Diagnostics). Cytospin slides were rehydrated with graded ethanol (100% 1 min, 70% 1 min, 50% 1 min), permeabilized with PBS + 0.1% Tween 20 (PBST) at RT for 10 min, incubated with hydrogen peroxide (Advanced Cell Diagnostics) at RT for 10 min, followed by incubation with 1:15 diluted protease III at RT for 10 min. Tissue sections were deparaffinized with xylene (2 changes × 5 min) and 100% ethanol (2 changes × 1 min), and then incubated with hydrogen peroxide for 10 min, followed by target retrieval in boiling water for 15 min, and incubation with Protease Plus (Advanced Cell Diagnostics) for 15 min at 40°C. Slides were hybridized with custom probes at 40°C for 2 h, and signals were amplified according to the manufacturer's instructions. The stained sections were scanned and digitized using an Olympus VS120 light or fluorescent microscope with a 40X 1.35 NA objective and Olympus confocal microscope with a 40X 0.6 NA or 60X 1.4 NA objective.

### Calculation of frequency of *ACE2* and *TMPRSS2*-positive cells in distinct anatomical airway regions as identified by scRNA-seq {#sec4.4.6}

Normalized log-transformed count+1 gene x cell matrix and meta-data were downloaded from <https://www.genomique.eu/cellbrowser/HCA/>, which represent 77,969 cells that passed quality control. Expression of *ACE2* and *TMPRSS2* were extracted from the matrix, and the number of cells with log normalized count \> 0 were calculated.

### RNA isolation and gene expression analysis by Taqman Assays {#sec4.4.7}

For qRT-PCR for *ACE2* and *TMPRSS2* expression in different airway regions, surface epithelial cells were isolated from freshly excised normal human lungs obtained from transplant donors by gentle scraping with a convex scalpel blade into F12 medium, excluding submucosal glands. Following centrifugation (450 g, 5 min, 4°C), the pelleted epithelial cells were resuspended in 1 mL of TRI Reagent (Sigma). Micro-dissected small airways and peripheral lung parenchyma were homogenized in 1 mL of TRI Reagent using a tissue homogenizer (Bertin Technologies). Debris was pelleted from the TRI Reagent by centrifugation, and the supernatant was used for RNA analysis.

The HBE cells growing on the transwell membrane were collected by excision of the whole membrane together with the cells using razor blade and lysed in TRI Reagent at 37°C shaker for 30 min. Total RNA was purified from the TRI Reagent lysates using the Direct-Zol RNA miniprep Kit (Zymo Research, cat\#R2051), and examined by NanoDrop One Spectrophotometer (ThermoFisher) for its quality and quantity. 1 μg of total RNA was reverse transcribed to cDNA by iScript Reverse Transcription Supermix (BioRad, Cat\#1708840) at 42°C for one h. Quantitative RT-PCR was performed using Taqman probes (Applied BioSystems) with SsoAdvanced Universal Probes Supermix (Bio-Rad, cat\#1725280) on QuantStudio6 Real-time PCR machine (Applied Biosystem). The house-keeping gene used for normalization of gene expression for *in vitro* cultured HBE was TATA-binding protein (TBP) gene. See [Key Resources Table](#sec4.1){ref-type="sec"} for detailed information about primers/probes.

### Assembly of SARS-CoV-2 WT and reporter cDNA constructs {#sec4.4.8}

Seven cDNA fragments covering the entire SARS-CoV-2 WA1 genome were amplified by RT-PCR using PrimeSTAR GXL HiFi DNA polymerase (TaKaRa). Junctions between each fragment contain non-palindromic sites BsaI (GGTCTCNˆNNNN) or BsmBI (CGTCTCNˆNNNN) with unique four-nucleotide cohesive ends. Fragment E and F contains two BsmBI sites at both termini, while other fragments harbor BsaI sites at the junction. Four-nucleotide cohesive ends of each fragment are indicated in [Figure 1](#fig1){ref-type="fig"}A. To assist the transcription of full-length viral RNA, we introduced a T7 promoter sequence into the upstream of fragment A, as well as a 25nt poly-A tail into the downstream of the fragment G. Each fragment was cloned into high-copy vector pUC57 and verified by Sanger sequencing. A silent mutation T15102A was introduced into a conserved region in nsp12 in plasmid D as a genetic marker. To enhance the efficiency of recovering SARS-CoV-2 virus in the cell culture, a sgRNA-N construct, encoding a 75nt leader sequence, N gene, 3′UTR, and a 25nt poly-A tail, was assembled under the control of a T7 promoter. Two reporter viruses, one containing GFP and the other harboring, a GFP-fused nLuc gene, were generated by replacing the ORF7 gene with the reporter genes.

#### Generation of full-length RNA transcript and recovery of recombinant viruses {#sec4.4.8.1}

Seven genomic cDNA fragments were digested with appropriate endonucleases, resolved on 0.8% agarose gels, excised and purified using a QIAquick Gel Extraction kit (QIAGEN). A full-length genomic cDNA was obtained by ligating seven fragments in an equal molar ratio with T4 DNA ligase (NEB). We then purified the ligated cDNA with chloroform and precipitated it in isopropanol. The full-length viral RNA or SARS-CoV-2 sgRNA-N were synthesized using the T7 mMESSAGE mMACHINE T7 transcription kit (Thermo Fisher) at 30°C for 4 h. The full-length SARS-CoV-2 transcript and sgRNA-N were mixed and electroporated into 8 × 10^6^ of Vero E6 cells. The cells were cultured as usual in the medium for two to three days.

### PCR of leader-containing sgRNAs {#sec4.4.9}

Viral replication in the electroporated cells was evaluated by amplification of leader sequence-containing sgRNAs. A forward primer targeting the leader sequence (5′- GTTTATACCTTCCCAGGTAACAAACC −3′) was paired with a reverse primer targeting M gene (5′- AAGAAGCAATGAAGTAGCTGAGCC −3′) or N gene (5′- GTAGAAATACCATCTTGGACTGAGATC −3′).

### Identification of the genetic marker {#sec4.4.10}

To confirm that the introduced T15102A mutation exists in the recombinant viruses, viral RNA was extracted using TRI Reagent (Thermo Fisher). A 1579 bp fragment in nsp12 of each virus was amplified by RT-PCR using primer pair 5′- GCTTCTGGTAATCTATTACTAGATAAACG-3′ and 5′- AAGACATCAGCATACTCCTGATTAGG −3′. The fragment was subjected to Sanger sequencing or digested with SacI enzyme (NEB).

### Northern Blot Analysis {#sec4.4.11}

Vero E6 cells were infected with SARS-CoV-2 isolate, icSARS-CoV-2-WT, icSARS-CoV-2-GFP or icSARS-CoV-2-GFP-nLuc at an MOI of 1. At 24 h post-infection, we extracted the total cellular RNA using TRIzol Reagent (Thermo Fisher). Poly A-containing messenger RNA was isolated from the total RNA using an Oligotex mRNA Mini Kit (QIAGEN). Messenger RNA (0.6-0.7 μg) was separated on an agarose gel and transferred to BrightStar-Plus membrane using a NorthernMax-Gly Kit (Invitrogen). Blots were hybridized with a biotin-labeled oligomer (5′- BiodT/GGCTCTGTTGGGAATGTTTTGTATGCG/BiodT-3′), then detected using a Chemiluminescent Nucleic Acid Detection Module (Thermo Fisher) using the iBright Western Blot Imaging System (Thermo Fisher).

### Generation of SAR-CoV-2 S protein-immunized mouse serum {#sec4.4.12}

The SAR-CoV-2 S and N genes was cloned into pVR21 3526 to generate virus replicon particles (VRPs), as previously described ([@bib1]). Briefly, SARS-CoV-2 S or N genes were inserted into pVR21, a vector encoding the genome of a VEEV strain 3526. The SARS-CoV-2-S-pVR21 construct, a plasmid containing the VEEV envelope glycoproteins, and a plasmid encoding the VEEV capsid protein were used to generate T7 RNA transcripts. The RNA transcripts were then electroporated into BHK cells. VRPs were harvested 48 h later and purified via high-speed ultra-centrifugation. Two groups of 10-week-old BALB/c mice (Jackson Labs) were then inoculated with the VRPs via footpad injection then boosted with the same dose once four weeks later. Serum samples were collected at 2 weeks post-boosting and were mixed together.

### Monoclonal antibody large-scale production {#sec4.4.13}

SARS-specific S230, S230.15, S227.14, S227.9 IgG, MERS-specific MERS-27, m336 IgG, and a Dengue-specific EDE1-C10 IgG antibody variable heavy and light chain genes were obtained, codon-optimized for human mammalian cell expression, and cloned into heavy and light-chain variable-gene-expressing plasmids encoding a human IgG1 Fc region as described previously ([@bib52]). One hundred μg of each variable heavy and light chain plasmids were co-transfected using an ExpiFectamine 293 transfection kit in Expi293F (Thermo) cells at 2.5 million cells/mL in 1L flasks in suspension. Transfected cell supernatants were harvested two days later, and the soluble antibody was purified using Pierce protein A beads (Thermo) followed by fast protein liquid chromatography (FPLC). MAbs were buffer exchanged with sterile 1XPBS. Purified mAbs were quality controlled by western blotting and Coomassie blue staining to confirm mAb purity.

### MERS-CoV, SARS-CoV, and SARS-CoV-2 neutralization assays {#sec4.4.14}

Recombinant viruses icMERS-CoV-nLuc, icSARS-CoV-nLuc, and icSARS-CoV-2-nLuc-GFP were tittered in Vero E6 cells to obtain a relative light units (RLU) signal of at least 20X the cell only control background. Vero E6 cells were plated at 20,000 cells per well the day prior in clear bottom black-walled 96-well plates (Corning 3904). Neutralizing antibody serum samples were tested at a starting dilution of 1:20 and mAb samples were tested at a starting dilution 50 μg/mL and were serially diluted 4-fold up to eight dilution spots. icMERS-CoV-nLuc, icSARS-CoV-nLuc, and icSARS-CoV-2-nLuc-GFP viruses were diluted and were mixed with serially diluted antibodies. Antibody-virus complexes were incubated at 37°C with 5% CO2 for 1 h. Following incubation, growth media was removed, and virus-antibody dilution complexes were added to the cells in duplicate. Virus-only controls and cell-only controls were included in each neutralization assay plate. Following infection, plates were incubated at 37°C with 5% CO2 for 48 h. After the 48 h incubation, cells were lysed, and luciferase activity was measured via Nano-Glo Luciferase Assay System (Promega) according to the manufacturer specifications. MERS-CoV, SARS-CoV, and SARS-CoV-2 neutralization titers were defined as the sample dilution at which a 50% reduction in RLU was observed relative to the average of the virus control wells.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For comparison of gene expression in response to cytokine exposure versus control (PBS) with one culture per code in each group, we performed Wilcoxon matched-pairs signed rank test by Graphpad Prism 8 built in function. For comparison of gene expression in response to cytokine exposure versus control (PBS) with more than one culture per code in each group, the linear mixed-effect models analysis were performed. The relative mRNA expression from Taqman assays were analyzed with linear mixed-effect models using the R package *Ime4* ([@bib7]), with treatment as fixed effect and code as random-effect factors. Statistical significance were evaluated with the R lmerTest package ([@bib48]), using the Satterthwarte's degrees of freedom method. Multiple post hoc comparisons of subgroups were performed using the R multcomp package ([@bib108]). For cell count data, generalized linear mixed-effect models (glmer) with Poisson distribution was used. Wilcoxon rank sum test was used to determine the statistical significance between unpaired two groups in [Figures 2](#fig2){ref-type="fig"}D, 2F, 2H, and [6](#fig6){ref-type="fig"} Bvi using Graphpad Prism 8. One-way ANOVA followed by Tukey test was used to determine the statistical significance between groups in Figure 6Bv using Graphpad Prism 8. The "n" numbers for each experiment are provided in the text and figures. p \< 0.05 was considered statistically significant.

### Co-localization of *ACE2* mRNA with marker-genes and quantification {#sec4.5.1}

RNA-ISH was performed on cytocentrifuged single cells using RNAscope Multiplex Fluorescent Assay v2, as described above, to assess colocalization of *ACE2* mRNA and airway epithelial cell markers, including *FOXJ1* (ciliated cells) and *MUC5B* (secretory cells). *ACE2* probe (channel 1) was combined with each of airway epithelial cell marker (channel 2). The stained cytospin slides were scanned and digitized using an Olympus VS120 whole slide scanner microscope with a 40X 0.9 numerical aperture objective. Using Fiji software ([@bib75]), quantification for colocalization was performed in the scanned images by an investigator blinded to slide identification. To calculate the occurrence of *ACE2* ^+^ cells in preparations, *ACE2* ^+^ cells and total cells were manually counted, and the frequency calculated. For quantitative co-localization analysis of *ACE2* with airway epithelial marker-defined cells, the number of visible *ACE2* signals (dots) was manually counted in each airway epithelial cell-marker-positive cell. The *ACE2* ^+^ signals were quantitated in 200 *FOXJ1* ^*+*^ *or MUC5B* ^+^ cells per subject. One or more dot signals defined a*n ACE2* ^+^ positive cell, while airway-epithelial-marker-positive cells were defined as cells expressing 10 or more dot signals for the epithelial marker.

### Quantification of *ACE2* and *TMPRSS2* gene expression in tonsillar surface epithelium {#sec4.5.2}

Human tonsil tissue sections were analyzed for *ACE2* and *TMPRSS2* expression using RNA-ISH. Tonsillar surface epithelial regions with positive RNA ISH signals (4 to 8 regions per donor) were selected for quantification. Signal counts were normalized to the number of cells as determined by DAPI nuclear stain in each region. For quantification, the stratified epithelial layer was divided into two layers: 1) surface (flattened epithelial) layer and 2) basal (cuboidal epithelial) layer.
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